MD Meymac
Our production site in Meymac, France, has undergone several changes in ownership throughout its history. Originally founded by Bristol-Myers Squibb in 1988, the facility was acquired by Salem Laboratories in 2012 and subsequently by Martin Dow Pharmaceuticals in 2015. In 2023, MD Meymac became part of the German Prange Group, expanding its capabilities and aligning with the Group’s strategic objectives as a CDMO in the pharmaceutical manufacturing sector.
The site operates in full compliance with current EU cGMP standards and has successfully undergone several regulatory inspections, with the most recent taking place in August 2024.
Pharmaceutical Forms
We offer full service in tablet manufacturing, covering all stages from blending through coating. In addition, we provide hard gelatin capsule filling and sachet production to support a wide range of pharmaceutical applications.
Packaging
Our expertise covers the entire process—from sourcing raw materials to final packaging in blisters, bottles, and sachets. By leveraging advanced technologies and maintaining an uncompromising commitment to quality, we ensure that every stage meets the highest industry standards.
Analytics
The in-house laboratories at MD Meymac are equipped with advanced instrumentation and staffed by experienced professionals dedicated to meeting the highest quality standards in the analytical testing of APIs, excipients, and drug products.
Pharmaceutical Transfer
A dedicated tech transfer team ensures the seamless and secure integration of your products into our facility. We focus on efficiency, precision, and minimal disruption throughout the entire transfer process.
Development
Comprehensive pharmaceutical development services provided by our sister company guide clients from early-stage research to full-scale commercial production.